@karina_castr6's GHK-Cu peptide claims, fact-checked

What did @karina_castr6 actually say?

Honestly, not much. The transcript is largely incoherent, repeating phrases about checking a code and a description link. What we can work with comes from the caption: she started using GHK-Cu as a personal experiment, reported seeing changes by day 6, and plans to document the process. She tagged dermatitis specifically, which is the claim that actually matters here.

The video leans heavily on the "experiment" framing, which at least signals she is not presenting this as a medical treatment. That is credit where it is due. But "day 6 and already seeing changes" is a red flag phrase in any health content. Six days is not enough time to draw conclusions about skin remodeling, and broadcasting that claim to 102,000 viewers without context is irresponsible regardless of intent.

Does the science back this up?

GHK-Cu (copper tripeptide-1) has real research behind it, more than most peptides trending on TikTok. The problem is that "real research" does not mean what people on social media think it means, and it certainly does not mean 6-day visible results are a validated outcome.

GHK-Cu has been studied for its role in wound healing, collagen synthesis, and anti-inflammatory signaling. Pickart et al. (2015, Journal of Aging Science) documented GHK-Cu's ability to activate genes involved in tissue repair and reduce pro-inflammatory cytokines. Gorouhi and Maibach (2009, International Journal of Cosmetic Science) reviewed copper peptide evidence in skin rejuvenation and found modest but real improvements in wrinkle depth and skin density with consistent topical use over weeks to months, not days. On the dermatitis angle specifically, some in vitro work suggests GHK-Cu may modulate TGF-beta pathways relevant to inflammatory skin conditions, but no robust randomized controlled trial has confirmed this for eczema or contact dermatitis in humans. The gap between lab findings and TikTok claims is wide.

What did they get wrong (or right)?

Right: using the word "experiment" and framing this as personal documentation rather than a recommendation. That framing matters and it is better than most peptide content on this platform.

Wrong: implying visible changes at day 6 are meaningful. Skin barrier repair and inflammatory resolution in dermatitis conditions typically require 4 to 12 weeks of consistent intervention to produce measurable outcomes, depending on severity. Anything perceived in 6 days is almost certainly a placebo response, natural disease fluctuation, or a confounding variable like moisturizer, reduced scratching, or stress changes. Dermatitis also waxes and wanes on its own.

Also wrong by omission: she does not mention route of administration, formulation, concentration, or whether this is a topical or injectable application. GHK-Cu is used both ways, and those are completely different products with different evidence profiles and different risk considerations. That missing context matters enormously for anyone watching.

What should you actually know?

GHK-Cu is one of the better-studied cosmetic peptides, but the evidence base for treating clinical dermatitis conditions is not there yet. Pickart's work is frequently cited but also largely foundational and mechanistic, not the kind of large-scale clinical trial that changes dermatology practice guidelines.

If you have dermatitis, the first-line options with actual clinical trial evidence include topical corticosteroids, calcineurin inhibitors like tacrolimus (Protopic), and for moderate-to-severe atopic dermatitis, biologics like dupilumab. GHK-Cu as an adjunct is not unreasonable to explore with a provider, but it is not a substitute, and no peptide should be positioned as one.

A few things worth knowing before going further:

• Topical GHK-Cu products are cosmetic-grade and unregulated for disease treatment claims.
• Injectable peptides sourced outside a licensed compounding pharmacy carry contamination and dosing risks.
• Six days is not a timeline. It is an anecdote.
• Dermatitis is a category, not a single condition. Atopic, contact, seborrheic, and nummular dermatitis have different drivers and respond differently to interventions.